1049 GMT - Investors are looking for evidence of GSK's pipeline progress as the patent for its HIV drug Dolutegravir will expire from 2028 in the U.S., Berenberg analysts say in a note. The British pharma giant's key growth drivers include its shingles vaccine Shingrix, its RSV shot Arexvy, HIV drugs Dovato, Cabenuva, Apretude and its lupus treatment Benlysta and asthma drug Nucala, the analyst say. GSK is expected to post sales and earnings growth in line with European non-obesity peers over the 2023-27 time period, driven by both its pharmaceuticals and vaccines units, Berenberg says. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 20, 2025 05:50 ET (10:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.